PharmAust Ltd
PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials… Read more
PharmAust Ltd (PAA) - Total Assets
Latest total assets as of June 2024: AU$11.12 Million AUD
Based on the latest financial reports, PharmAust Ltd (PAA) holds total assets worth AU$11.12 Million AUD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PharmAust Ltd - Total Assets Trend (2001–2024)
This chart illustrates how PharmAust Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PharmAust Ltd - Asset Composition Analysis
Current Asset Composition (June 2024)
PharmAust Ltd's total assets of AU$11.12 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 87.3% |
| Accounts Receivable | AU$146.01K | 1.3% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how PharmAust Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmAust Ltd's current assets represent 100.0% of total assets in 2024, an increase from 47.7% in 2001.
- Cash Position: Cash and equivalents constituted 87.3% of total assets in 2024, up from 38.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 40.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
PharmAust Ltd Competitors by Total Assets
Key competitors of PharmAust Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
USA | $11.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $202.45 Million |
|
Jacobio Pharmaceuticals Group Co. Ltd.
PINK:JBPHF
|
USA | $1.29 Billion |
|
genOway Société anonyme
F:JEH
|
Germany | €38.82 Million |
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
USA | $57.47 Million |
|
ToolGen Inc.
KQ:199800
|
Korea | ₩68.38 Billion |
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
USA | $2.58 Million |
|
JW (Cayman) Therapeutics Co. Ltd
PINK:JWCTF
|
USA | $1.42 Billion |
PharmAust Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - PharmAust Ltd generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PharmAust Ltd is currently not profitable relative to its asset base.
PharmAust Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.42 | 2.24 | 3.28 |
| Quick Ratio | 12.42 | 2.24 | 2.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$10.23 Million | AU$ 1.67 Million | AU$ 2.10 Million |
PharmAust Ltd - Advanced Valuation Insights
This section examines the relationship between PharmAust Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.66 |
| Latest Market Cap to Assets Ratio | 3.31 |
| Asset Growth Rate (YoY) | 81.5% |
| Total Assets | AU$11.12 Million |
| Market Capitalization | $36.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PharmAust Ltd's assets at a significant premium ( 3.31x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: PharmAust Ltd's assets grew by 81.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PharmAust Ltd (2001–2024)
The table below shows the annual total assets of PharmAust Ltd from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | AU$11.12 Million | +81.47% |
| 2023-06-30 | AU$6.13 Million | -39.17% |
| 2022-06-30 | AU$10.08 Million | -7.99% |
| 2021-06-30 | AU$10.95 Million | +1.93% |
| 2020-06-30 | AU$10.75 Million | +25.02% |
| 2019-06-30 | AU$8.60 Million | +2.84% |
| 2018-06-30 | AU$8.36 Million | +1.99% |
| 2017-06-30 | AU$8.20 Million | +30.97% |
| 2016-06-30 | AU$6.26 Million | -34.29% |
| 2015-06-30 | AU$9.52 Million | +15.99% |
| 2014-06-30 | AU$8.21 Million | +806.72% |
| 2013-06-30 | AU$905.42K | -62.41% |
| 2012-06-30 | AU$2.41 Million | +66.02% |
| 2011-06-30 | AU$1.45 Million | -78.75% |
| 2010-06-30 | AU$6.83 Million | -9.81% |
| 2009-06-30 | AU$7.57 Million | -5.28% |
| 2008-06-30 | AU$7.99 Million | -21.39% |
| 2007-06-30 | AU$10.17 Million | +10.89% |
| 2006-06-30 | AU$9.17 Million | +73.84% |
| 2005-06-30 | AU$5.27 Million | +482.91% |
| 2004-06-30 | AU$904.88K | -63.98% |
| 2003-06-30 | AU$2.51 Million | -48.99% |
| 2002-06-30 | AU$4.93 Million | -1.29% |
| 2001-06-30 | AU$4.99 Million | -- |